Pulmonary Arterial Hypertension are caused by high blood pressure in lungs arteries due to connective tissue disease, congenital heart disease, coronary artery disease, liver disease, emphysema and blood clots to lungs.

Growing prevalence of pulmonary arterial hypertension across globe has contributed in target market growth. Increased awareness among patients coupled with high diagnosis rate has become another factor in target market growth. Rising government initiatives across globe to prevent this disease is expected to fuel the demand for Pulmonary Arterial Hypertension market growth over the forecast period.

The report “Pulmonary Arterial Hypertension Market, By Drug Class (PDE-5 Inhibitors, Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin & Prostacyclin Analogs), By Type (Generics, Branded), By Route of Administration (Inhalational, Intravenous/Subcutaneous, Oral), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

Key Highlights:

• In August 2023, a study led by ‘The Goncharova Lab’ at UC Davis Health has found the new treatment or potential therapy for treating pulmonary arterial hypertension. The research team discovered the growth suppressor TSC2 which could potentially return the arteries in lung to biological level.

Analyst View:

Presence of major players and well-planned reimbursement structure has become a leading factor in target market growth. Further, increased geriatric population coupled with rising incidence of chronic diseases across globe is anticipated to increase the demand for Pulmonary Arterial Hypertension market growth. As a result, market competition is intensifying, and both big international corporations and start-ups are vying to establish position in the market.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on

“Pulmonary Arterial Hypertension Market, By Drug Class (PDE-5 Inhibitors, Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin & Prostacyclin Analogs), By Type (Generics, Branded), By Route of Administration (Inhalational, Intravenous/Subcutaneous, Oral), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

Key Market Insights from the report:

Pulmonary Arterial Hypertension Market accounted for US$ 7.3 billion in 2022 and is estimated to be US$ 12.2 billion by 2032 and is anticipated to register a CAGR of 5.5%. The Pulmonary Arterial Hypertension Market is segmented based on Drug Class, Type, Route of Administration and Region.

• Based on Drug Class, Pulmonary Arterial Hypertension Market is segmented into PDE-5 Inhibitors, Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin & Prostacyclin Analogs.
• Based on Type, Pulmonary Arterial Hypertension Market is segmented into Generics, Branded.
• Based on Route of Administration, Pulmonary Arterial Hypertension Market is segmented into Inhalational, Intravenous/Subcutaneous, Oral.
• By Region, the Pulmonary Arterial Hypertension Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Competitive Landscape & their strategies of Pulmonary Arterial Hypertension Market:

The prominent players operating in the Pulmonary Arterial Hypertension Market includes, United Therapeutics Corporation, Johnson & Johnson, Bayer, Gilead Sciences Inc., GlaxoSmithKline, Lupin Pharmaceuticals Inc., Novartis, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc., Viatris Inc., and others.

To know more

Contact Us:

Sales

Prophecy Market Insights

 U.S.  1 860 531 2574

RoW: 917775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com